

Roquette to Spotlight Moisture Sensitive Excipients Portfolio at CPHI 2023

Roquette Pharma Solutions, Stand 5G29, CPHI, Barcelona, Spain, October 24-26, 2023

La Madeleine (France), 28 September, 2023 – Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, is set to unveil its extensive range of excipients for moisture protection – including three new product grades – at CPHI Barcelona next month. The versatile portfolio offers enhanced stability and moisture protection for sensitive formulations, as well as providing pharmaceutical and nutraceutical manufacturers with a comprehensive range of low water activity (Aw) excipients, suitable for any manufacturing method or dosage form. Visitors to the Roquette stand are invited to discover how these solutions can help keep essential treatments stable, safe and effective for longer.

In addition, Roquette has been shortlisted as a finalist in the “Finished Formulation” category of the CPHI Pharma Awards for its PEARLITOL® 200 GT mannitol.

Moisture sensitivity: the challenges and opportunities

Current forecasts estimate the value of the global oral solid dosage segment to exceed 1 trillion USD by 2032. A similar level of success is predicted in the nutraceutical sector, particularly in the probiotics space, which is expected to post an impressive 14 percent CAGR between 2023-2030. To fully harness the myriad growth opportunities on offer, solid oral dosage formulators must master the issue of stability of moisture sensitive active pharma and nutraceutical ingredients.

The efficacy and stability of moisture sensitive active ingredients, such as probiotic strains, dabigatran (an anti-coagulant), tiotropium (a medication used in the treatment of chronic obstructive pulmonary disease [COPD]) and many more, can be negatively affected by the presence of excess water within the formulation. Moisture management has in the past had to give way to other critical considerations, such as flowability, compactability or homogeneity, leading manufacturers to select excipients, which require a lengthy additional drying process. In recent years, specialized excipients have emerged to streamline and expedite the processing of moisture sensitive active pharmaceutical and nutraceutical ingredients, but these solutions are often specific to a particular delivery format or processing method, denying manufacturers complete freedom. In response to this issue, Roquette proudly sets out its vision for innovation without limits with the launch of its complete moisture sensitive excipients portfolio at CPHI Barcelona 2023.

A commitment to comprehensive solutions

“Choosing the right excipients to provide optimum performance is a crucial part of the drug development process. That’s why we continuously look to develop new excipients that address some of the fundamental challenges inherent to drug delivery, such as moisture instability,” comments Paul Smaltz, Vice President of Pharmaceutical Solutions at Roquette. “Today’s announcement of the extension of our moisture protection portfolio is the latest expression of our commitment to providing holistic solutions that facilitate the medications that save and improve lives worldwide. Our extensive experience supporting the



production of virtually every dosage form, alongside a relentless pursuit of enhanced scientific knowledge, has culminated in a portfolio that can truly be labeled 'complete.' We can't wait to unveil the range – including three all-new product grades – at CPHI, and show the industry how the right excipients can turn moisture sensitive formulations from a challenge to an opportunity.”

CPHI Worldwide attendees are urged to add a visit to stand 5G29 to their event itineraries to discover everything the new-look portfolio has to offer and many more exclusive insights from the world leader in quality excipient solutions. To learn more about Roquette, visit: www.roquette.com.

About Roquette: *“Improving well-being by offering the best of nature”*

Roquette is a family-owned global leader in plant-based ingredients, a pioneer of plant proteins and a leading provider of pharmaceutical excipients. Founded in 1933, the company currently operates in more than 100 countries, has a turnover of around 5 billion euros, and employs more than 8,000 people worldwide.

Life and nature have been our sources of inspiration for decades. All our raw materials are of natural origin. From them, we enable a whole new plant protein cuisine; we offer pharmaceutical solutions that play a key role in medical treatments; and we develop innovative ingredients for food, nutrition, and health markets. We truly unlock the potential of nature to improve, cure and save lives.

Thanks to a constant drive for innovation and a long-term vision, we are committed to improving the well-being of people all over the world. We put sustainable development at the heart of our concerns, while taking care of resources and territories. We are determined to create a better and healthier future for all generations.

Discover more about Roquette at this [link](#).

Media contacts

Roquette Global Pharmaceutical Communications

Sally Khalvati

sally.khalvati@roquette.com

BDB Agency

roquette@bdb.co.uk

+44 161 925 4700